$NRXP
NRX Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000155837022017772 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.432M $5.012M $13.82M
YoY Change -88.33% -63.74% 8077.98%
% of Gross Profit
Research & Development $4.456M $4.129M $6.276M
YoY Change -30.52% -34.21% 44.88%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K $640.00
YoY Change 156.41% 56.25%
% of Gross Profit
Operating Expenses $9.888M $9.141M $20.10M
YoY Change -81.33% -54.52% 290.34%
Operating Profit -$9.141M -$20.10M
YoY Change -54.52% 290.34%
Interest Expense $152.0K $58.00K $5.368K
YoY Change -68.42% 980.48% -57.1%
% of Operating Profit
Other Income/Expense, Net -$505.0K $58.00K -$673.9K
YoY Change -102.33% -108.61% 5285.98%
Pretax Income -$10.24M -$9.083M -$20.77M
YoY Change -66.74% -56.28% 302.45%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.24M -$9.083M -$20.77M
YoY Change -66.74% -56.28% 302.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.40
Diluted Earnings Per Share -$0.15 -$0.14 -$0.40
COMMON SHARES
Basic Shares Outstanding 67.64M 67.64M 51.74M
Diluted Shares Outstanding 66.45M 51.05M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.05M $18.25M $38.88M
YoY Change -27.35% -53.07% 97060.34%
Cash & Equivalents $20.05M $18.25M $38.88M
Short-Term Investments
Other Short-Term Assets $5.741M $6.552M $6.351M
YoY Change 12.37% 3.17% 11024.35%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $25.80M $24.80M $45.23M
YoY Change -21.15% -45.17% 46485.44%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $23.00K $15.92K
YoY Change 40.0% 44.46%
Total Long-Term Assets $21.00K $23.00K $15.92K
YoY Change 40.0% 44.46% -99.73%
TOTAL ASSETS
Total Short-Term Assets $25.80M $24.80M $45.23M
Total Long-Term Assets $21.00K $23.00K $15.92K
Total Assets $25.82M $24.82M $45.25M
YoY Change -21.12% -45.14% 650.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.076M $2.168M $5.559M
YoY Change -43.69% -61.0% 1366.09%
Accrued Expenses $4.855M $5.067M $1.996M
YoY Change 104.42% 153.86%
Deferred Revenue $56.00K $775.3K
YoY Change -92.78%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.703M $0.00 $515.1K
YoY Change 1387.07% -100.0%
Total Short-Term Liabilities $15.59M $8.042M $36.28M
YoY Change 30.71% -77.84% 9468.3%
LONG-TERM LIABILITIES
Long-Term Debt $2.822M $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.822M $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.59M $8.042M $36.28M
Total Long-Term Liabilities $2.822M $0.00 $0.00
Total Liabilities $18.41M $8.042M $36.28M
YoY Change 54.38% -77.84% 1181.83%
SHAREHOLDERS EQUITY
Retained Earnings -$223.0M -$212.8M -$152.4M
YoY Change 21.69% 39.56%
Common Stock $67.00K $68.00K $54.81K
YoY Change 13.56% 24.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.409M $16.78M $8.967M
YoY Change
Total Liabilities & Shareholders Equity $25.82M $24.82M $45.25M
YoY Change -21.12% -45.14% 650.2%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$10.24M -$9.083M -$20.77M
YoY Change -66.74% -56.28% 302.45%
Depreciation, Depletion And Amortization $1.000K $1.000K $640.00
YoY Change 156.41% 56.25%
Cash From Operating Activities -$8.318M -$6.266M -$12.01M
YoY Change -26.26% -47.85% 18478.89%
INVESTING ACTIVITIES
Capital Expenditures -$1.000K -$5.000K -$3.830K
YoY Change 156.41% 30.55%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $1.000K -$5.000K -$3.830K
YoY Change -356.41% 30.55% -101.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.12M -28.00K 37.52M
YoY Change 822826.83% -100.07% -18722.08%
NET CHANGE
Cash From Operating Activities -8.318M -6.266M -12.01M
Cash From Investing Activities 1.000K -5.000K -3.830K
Cash From Financing Activities 10.12M -28.00K 37.52M
Net Change In Cash 1.805M -6.299M 25.50M
YoY Change -116.0% -124.7% 63627.17%
FREE CASH FLOW
Cash From Operating Activities -$8.318M -$6.266M -$12.01M
Capital Expenditures -$1.000K -$5.000K -$3.830K
Free Cash Flow -$8.317M -$6.261M -$12.01M
YoY Change -26.26% -47.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66449593
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51739452
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65532409
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43290675
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67641314
dei Entity Central Index Key
EntityCentralIndexKey
0001719406
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-37049000
dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58510550
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M15D
CY2022Q1 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P10Y0M0D
CY2022Q1 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeitedd
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeitedd
P9Y1M6D
CY2022Q1 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y0M0D
CY2022Q2 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P10Y0M0D
CY2022Q2 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeitedd
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeitedd
P0Y0M0D
CY2022Q2 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M9D
CY2022Q3 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P10Y0M0D
CY2022Q3 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeitedd
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeitedd
P0Y0M0D
CY2022Q3 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y6M0D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38302
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
254-6134
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67641314
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18249000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27605000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6552000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
24801000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
32714000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2022Q3 us-gaap Assets
Assets
24824000
CY2021Q4 us-gaap Assets
Assets
32729000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2168000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3687000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5067000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2022Q3 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
751000
CY2021Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
469000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4582000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
56000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
292000
CY2021Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
518000
CY2022Q3 us-gaap Liabilities
Liabilities
8042000
CY2021Q4 us-gaap Liabilities
Liabilities
11923000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67641314
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58810550
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
68000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
59000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
229470000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203990000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212756000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183243000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16782000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24824000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32729000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4129000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6276000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12571000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13844000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5012000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13823000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21876000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28382000
nrxp Settlement Expense
SettlementExpense
21366000
nrxp Expense Reimbursement
ExpenseReimbursement
771000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9141000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
20099000
us-gaap Operating Expenses
OperatingExpenses
34447000
us-gaap Operating Expenses
OperatingExpenses
62821000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9141000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20099000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34447000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62821000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
95000
us-gaap Interest Income Other
InterestIncomeOther
119000
CY2021Q3 us-gaap Interest Expense
InterestExpense
5000
us-gaap Interest Expense
InterestExpense
3000
us-gaap Interest Expense
InterestExpense
16000
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-37000
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-16537000
nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
4582000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
236000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
823000
CY2021Q3 nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
-408000
nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
-763000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
58000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16950000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4934000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
165000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9083000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-37049000
us-gaap Net Income Loss
NetIncomeLoss
-29513000
us-gaap Net Income Loss
NetIncomeLoss
-62656000
nrxp Deemed Dividend Warrants
DeemedDividendWarrants
255822000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9083000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37049000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29513000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-318478000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.14
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.72
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.45
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.36
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.14
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.72
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.45
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.36
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66449593
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51739452
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65532409
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43290675
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2022Q1 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
2020000
CY2022Q1 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
22980000
CY2022Q1 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
17000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1334000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13448000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
31689000
CY2022Q2 nrxp Private Placement Issuance Costs
PrivatePlacementIssuanceCosts
342000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
987000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6982000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25352000
CY2021Q2 nrxp Financing Net Of Issuance Costs
FinancingNetOfIssuanceCosts
1900000
CY2021Q2 nrxp Stock Issued During Period Value New Issues From Private Investment In Equity
StockIssuedDuringPeriodValueNewIssuesFromPrivateInvestmentInEquity
8100000
CY2022Q3 nrxp Private Placement Issuance Costs
PrivatePlacementIssuanceCosts
28000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
541000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9083000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16782000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-43771000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6927000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
60852000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
372000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25489000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
6391000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1562000
CY2021Q2 nrxp Net Of Redemptions And Issuance Costs
NetOfRedemptionsAndIssuanceCosts
1413000
CY2021Q2 nrxp Stock Repurchased During Period Value Merger And Recapitalization Net Of Redemptions And Issuance Costs
StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts
64836000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4850000
CY2021Q2 nrxp Adjustments To Additional Paid In Capital Modifications Of Stock Options Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfStockOptionsDueToBusinessCombination
1014000
CY2021Q2 nrxp Adjustments To Additional Paid In Capital Modifications Of Warrant Issued Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfWarrantIssuedDueToBusinessCombination
2331000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
938000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-117000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-39767000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1134000
CY2021Q3 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
3669000
CY2021Q3 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
27359000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47319000
CY2021Q3 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
7926000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1560000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
8482000
us-gaap Net Income Loss
NetIncomeLoss
-29513000
us-gaap Net Income Loss
NetIncomeLoss
-62656000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
2000
us-gaap Share Based Compensation
ShareBasedCompensation
2862000
us-gaap Share Based Compensation
ShareBasedCompensation
6215000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-236000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-823000
nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
-763000
us-gaap Paid In Kind Interest
PaidInKindInterest
15000
nrxp Noncash Settlement Expense
NoncashSettlementExpense
21366000
nrxp Non Cash Consulting Expense
NonCashConsultingExpense
12776000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-831000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1443000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6050000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1519000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1854000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2991000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-595000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31437000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26423000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
11000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16699000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11050000
nrxp Proceeds From Issuance Of Common Stock And Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockAndExerciseOfStockOptions
9624000
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-518000
nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
22610000
nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
27359000
nrxp Proceeds From Repayments Of Notes Payable Assumed In Merger
ProceedsFromRepaymentsOfNotesPayableAssumedInMerger
-1100000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-177000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22092000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63455000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9356000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
37025000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27605000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1859000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18249000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38884000
nrxp Reclassification Of Settlement Liability Upon Issuance Of Warrant
ReclassificationOfSettlementLiabilityUponIssuanceOfWarrant
60852000
nrxp Reclassification Of Legacy Warrants To Warrant Liability
ReclassificationOfLegacyWarrantsToWarrantLiability
38220000
nrxp Reclassification Of Warrant Liability Upon Exercise Of Warrant
ReclassificationOfWarrantLiabilityUponExerciseOfWarrant
38120000
nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
726000
nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
1027000
nrxp Extinguishment Of Paycheck Protection Program Loan
ExtinguishmentOfPaycheckProtectionProgramLoan
121000
us-gaap Stock Issued1
StockIssued1
17000
CY2022Q3 us-gaap Cash
Cash
18200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the Earnout Cash liability, valuation of common and preferred stock, stock options, warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. </p>
nrxp Option Exchange Ratio Shares Earnout Shares For Common Stockholders
OptionExchangeRatioSharesEarnoutSharesForCommonStockholders
22209280
nrxp Option Exchange Ratio Value Earnout Cash For Common Stockholders
OptionExchangeRatioValueEarnoutCashForCommonStockholders
88800000
nrxp Business Combination Cash Held In Trust Used For Funding Net Of Redemption
BusinessCombinationCashHeldInTrustUsedForFundingNetOfRedemption
4363000
nrxp Business Combination Cash Inflow Pipe Financing Net Of Transaction Costs
BusinessCombinationCashInflowPipeFinancingNetOfTransactionCosts
8100000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1413000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11050000
CY2021Q2 nrxp Business Combination Equity Effect Of Cash Held In Trust Used For Funding Net Of Redemption
BusinessCombinationEquityEffectOfCashHeldInTrustUsedForFundingNetOfRedemption
4363000
CY2021Q2 nrxp Business Combination Recognized Identifiable Assets Acquired Net Working Capital Assumed
BusinessCombinationRecognizedIdentifiableAssetsAcquiredNetWorkingCapitalAssumed
962000
CY2021Q2 nrxp Business Combination Effect On Equity Of Notes Payable Assumed
BusinessCombinationEffectOnEquityOfNotesPayableAssumed
1100000
CY2021Q2 nrxp Business Combination Effect On Equity Of Placement Warrants Assumed
BusinessCombinationEffectOnEquityOfPlacementWarrantsAssumed
1984000
CY2021Q2 nrxp Shares Subject To Mandatory Redemption Legacy Warrants Fair Value Of Shares
SharesSubjectToMandatoryRedemptionLegacyWarrantsFairValueOfShares
38220000
CY2021Q2 nrxp Business Combination Effect On Equity Of Earnout Cash
BusinessCombinationEffectOnEquityOfEarnoutCash
25520000
CY2021Q2 nrxp Net Of Redemptions And Issuance Costs
NetOfRedemptionsAndIssuanceCosts
1413000
CY2021Q2 nrxp Stock Repurchased During Period Value Merger And Recapitalization Net Of Redemptions And Issuance Costs
StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts
64836000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
4853000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3224000
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
555000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
345000
CY2022Q3 nrxp Receivables Due From Manufacturers
ReceivablesDueFromManufacturers
547000
CY2022Q3 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
316000
CY2021Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
512000
CY2022Q3 nrxp Prepaid Legal Expenses
PrepaidLegalExpenses
281000
CY2021Q4 nrxp Prepaid Manufacturing Expenses Current
PrepaidManufacturingExpensesCurrent
1028000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6552000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2022Q3 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1624000
CY2021Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1055000
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
554000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
456000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
264000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
743000
CY2022Q3 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
2625000
CY2021Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
121000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5067000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
3238338
CY2021Q3 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
31100000
nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
7824727
nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
3642515
nrxp Proceeds From Sale Of Stock New Issuances And Sale Of Stock Options And Warrants
ProceedsFromSaleOfStockNewIssuancesAndSaleOfStockOptionsAndWarrants
23000000.0
nrxp Proceeds From Sale Of Stock New Issuances And Sale Of Stock Options And Warrants
ProceedsFromSaleOfStockNewIssuancesAndSaleOfStockOptionsAndWarrants
39600000
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2334370
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3830586
CY2021Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9200000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16700000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2654579
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.86
CY2021Q3 nrxp Shares Of Stock Issued For Payment Of Consulting Services
SharesOfStockIssuedForPaymentOfConsultingServices
634045
nrxp Shares Of Stock Issued For Payment Of Consulting Services
SharesOfStockIssuedForPaymentOfConsultingServices
834045
CY2021Q3 nrxp Non Cash Consulting Expense
NonCashConsultingExpense
7900000
nrxp Non Cash Consulting Expense
NonCashConsultingExpense
12800000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9305790
CY2021 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y11M1D
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.09
CY2021Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
4942000
nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
8215963
nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P5Y6M
nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
3.11
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17521753
nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y9M10D
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.29
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2400315
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.28
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4224000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
552000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.00
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
45367
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.05
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2906948
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.54
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1006000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
350000
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.52
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
550833
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.76
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2706115
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
174000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
80000
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.69
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
131536
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.31
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
278000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1064852
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.84
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
196000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
541000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1560000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2862000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6215000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
100000

Files In Submission

Name View Source Status
0001558370-22-017772-index-headers.html Edgar Link pending
0001558370-22-017772-index.html Edgar Link pending
0001558370-22-017772.txt Edgar Link pending
0001558370-22-017772-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20220930.xsd Edgar Link pending
nrxp-20220930x10q.htm Edgar Link pending
nrxp-20220930xex10d1.htm Edgar Link pending
nrxp-20220930xex10d1001.jpg Edgar Link pending
nrxp-20220930xex10d1002.jpg Edgar Link pending
nrxp-20220930xex31d1.htm Edgar Link pending
nrxp-20220930xex31d2.htm Edgar Link pending
nrxp-20220930xex32d1.htm Edgar Link pending
nrxp-20220930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
nrxp-20220930_lab.xml Edgar Link unprocessable
nrxp-20220930x10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nrxp-20220930_cal.xml Edgar Link unprocessable
nrxp-20220930_pre.xml Edgar Link unprocessable
nrxp-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable